During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival…

On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is…

    Job Title: Scientific and Patient Information Manager Position Type: Full-time/permanent  Location: Home-based/Remote. Must be based in the UK, Germany, France or Spain Travel required: 25 days/year (approx.) Gross salary: 40.000 – 46.000 euros (depending…